Navigation Links
GENova Biotherapeutics secures new cancer drugs targets
Date:9/17/2009

NEW YORK, Sept. 17 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it has signed a collaboration deal with Beckpharma Ltd. ("Beckpharma") -a pharmaceutical development company also involved in cancer treatments.

The two companies are joining forces in their mutual mission to identify, acquire, and out-license promising cancer drugs in an effort that will not only save millions on GENova's R D budget, but at the same time will significant increase GENova's distribution, the deal with Beckpharma is the latest deal in a string of deals that GENova has recently done in a continued effort to increase its IP portfolio and increase its distribution network.

"By combining our efforts with Beckpharma's, we are casting a wider net when it comes to sourcing new cancer drug targets. Beckpharma has close relationships with academic research institutions around the world, and now, through this collaboration, their industry contacts become ours, and vice versa," says Aaron Whiteman, CEO for GENova.

This collaboration will bolster GENova's acquisition activities and funnel more promising drug targets into its drug development pipeline. GENova will also leverage the scientific expertise of Beckpharma's Research and Development Team, as well as its established distribution channels with Big Pharmaceutical companies.

Furthermore, scientists in both GENova and Beckpharma are examining their current IP portfolios to gain insight into possible synergies between their drug targets, and the possibility of making a stronger, better, combined product by coordinating their biotechnologies.

"This is a positive step for GENova," says Whiteman. "Through our collaboration with Beckpharma we are gaining access to their technologies and relationships, and we hope to leverage that to bring our patents to market faster, and thus start reaping payments on our potential blockbuster drug patents".

About Beckpharma

Beckpharma is a pharmaceutical development company whose mission is to take marketed products, as well as products at all stages of clinical development, from targeted academic institutes and other sources, add value to those products, and then commercialise them through its own resources or through industry partners in Europe, North America and other suitable territories.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at: www.genovabio.com

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GENova Biotherapeutics signs engagement agreement with PacificWave Partners Limited
2. GENova and TheraGlass in advanced negotiations
3. GENova Biotherapeutics forming academic partnerships
4. GENova Biotherapeutics signs collaboration agreement with Prime BioResearch
5. GENova Biotherapeutics and Prime BioResearch signs LOI on diabetes and cancer cure
6. GENova gains access to Big Pharma
7. GENova appoints Dr. Wang Chong to Scientific Advisory Board
8. GENova appoints Dr. Philip Gould to Scientific Advisory Board
9. GENova issues clarifying press release
10. GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
11. GENova files patent for new breast cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is ... natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO ... to create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... ... December 05, 2016 , ... The ... care facility – Avamere Transitional Care of Puget Sound ; located at ... health care center will provide patients recovering from illness or injury with intensive ...
(Date:12/5/2016)... VA (PRWEB) , ... December 05, 2016 , ... ... today announced it has been featured in SuperbCrew magazine, a leading online tech ... tech world. This interview, now featured on SuperbCrew.com, explores the state of enterprise ...
(Date:12/5/2016)... ... ... Researchers at Johns Hopkins All Children’s Hospital want to learn more about ... of three years, researchers will study concussions and changes in brain function by monitoring ... sensors, will track the location and force of the hit. The sensors store data ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy ... through tomorrow, December 6th, sparks a conversation about epilepsy, bearing down on the ... 26 people will be diagnosed with epilepsy within their lifetime. With such a ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Sanovas, Inc., a life science asset holding ... its wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed ... - http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed ...
(Date:12/5/2016)... 2016  CVS Health, the nation,s largest pharmacy innovation ... score of 100 percent on the Corporate Equality Index ... an annual national benchmarking survey and report on corporate ... the Human Rights Campaign Foundation. "Our ... colleagues, customers and suppliers bring to CVS Health," said ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 /PRNewswire/ ... announced preliminary safety and efficacy data from a ... selective MDM2 inhibitor, suggesting that DS-3032 may be ... acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome ... of the phase 1 study of DS-3032 were presented ...
Breaking Medicine Technology: